IL131349A - Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors - Google Patents

Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors

Info

Publication number
IL131349A
IL131349A IL13134998A IL13134998A IL131349A IL 131349 A IL131349 A IL 131349A IL 13134998 A IL13134998 A IL 13134998A IL 13134998 A IL13134998 A IL 13134998A IL 131349 A IL131349 A IL 131349A
Authority
IL
Israel
Prior art keywords
group
halofuginone
hydrogen
compound
tumor
Prior art date
Application number
IL13134998A
Other languages
English (en)
Hebrew (he)
Other versions
IL131349A0 (en
Inventor
Nagler Arnon
Pines Mark
Original Assignee
Israel State
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel State, Hadasit Med Res Service filed Critical Israel State
Publication of IL131349A0 publication Critical patent/IL131349A0/xx
Publication of IL131349A publication Critical patent/IL131349A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13134998A 1997-02-11 1998-02-11 Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors IL131349A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/797,703 US6028075A (en) 1997-02-11 1997-02-11 Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
PCT/IL1998/000070 WO1998034613A1 (fr) 1997-02-11 1998-02-11 Compositions pharmaceutiques contenant de la quinazolinone et destinees a la prevention de la neoformation de vaisseaux sanguins et au traitement d'affections malignes

Publications (2)

Publication Number Publication Date
IL131349A0 IL131349A0 (en) 2001-03-19
IL131349A true IL131349A (en) 2004-08-31

Family

ID=25171574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13134998A IL131349A (en) 1997-02-11 1998-02-11 Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors

Country Status (11)

Country Link
US (3) US6028075A (fr)
EP (1) EP1007044B1 (fr)
JP (1) JP2001518075A (fr)
KR (1) KR100518106B1 (fr)
AT (1) ATE367158T1 (fr)
AU (1) AU738516B2 (fr)
CA (1) CA2280850C (fr)
DE (1) DE69838099T2 (fr)
ES (1) ES2290983T3 (fr)
IL (1) IL131349A (fr)
WO (1) WO1998034613A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
JP2001518062A (ja) * 1997-03-31 2001-10-09 農務省 農務調査機構 肺繊維症の治療
DE69927987T2 (de) * 1998-08-13 2006-11-09 Hadasit Medical Research Services & Development Co. Ltd. Hemmung von mit gewebetrauma verbundenen pathogenen prozessen
IL148246A0 (en) * 1999-09-09 2002-09-12 Hadasit Med Res Service Promotion of wound healing
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CN1518447A (zh) * 2001-04-23 2004-08-04 �������Ǵ�ѧר������� 作为抗血管生成剂的新的苯邻二甲酰亚胺模拟物的合成和评估
US8349853B2 (en) * 2001-09-05 2013-01-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
JP2005501887A (ja) * 2001-09-05 2005-01-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 癌の処置における組成物およびその使用
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
EP1558261A4 (fr) * 2002-10-31 2008-06-04 Israel State Compositions de quinazolinone destinees a reguler l'expression genetique dans des processus pathologiques
MX2007006279A (es) * 2004-12-15 2007-06-14 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
WO2006090376A2 (fr) * 2005-02-23 2006-08-31 Collgard Biopharmaceuticals Ltd. Composition pharmaceutique d'enantiomeres d isoles de derives de quinazolinone halofuginone
CN101273130B (zh) 2005-07-07 2012-05-30 耶路撒冷希伯来大学伊森姆研究发展公司 用于下调h19的核酸物质及其使用方法
US20070160640A1 (en) * 2006-01-12 2007-07-12 Eun-Hyun Jang Halofuginone delivering vascular medical devices
US20080025917A1 (en) * 2006-04-10 2008-01-31 Malcolm Whitman Methods for modulating formation and progression of cellulite
JP2010511427A (ja) * 2006-12-01 2010-04-15 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ コラーゲン阻害剤を含む医療デバイス
WO2008087641A2 (fr) 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents nucléotidiques de silençage de h19 destinés au traitement de l'arthrite rhumatoïde
US8410120B2 (en) * 2007-01-21 2013-04-02 Mark Pines Composition and method for treating or preventing skeletal muscle fibrosis
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
US20110212100A1 (en) * 2007-08-15 2011-09-01 Tracy Keller Methods for modulating development and expansion of il-17 expressing cells
WO2010019210A2 (fr) 2008-08-11 2010-02-18 President And Fellows Of Harvard College Analogues d'halofuginone pour l'inhibition d'arnt synthétases et leurs utilisations
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
CA2861840C (fr) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Derives d'halofuginol et leur utilisation dans des compositions cosmetiques et pharmaceutiques
WO2015034330A1 (fr) * 2013-09-09 2015-03-12 가톨릭대학교 산학협력단 Composition pour le traitement ou la prévention de maladies osseuses, comprenant de l'halofuginone comme principe actif
CN105497091B (zh) * 2016-01-05 2020-01-24 香港浸会大学 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) * 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
CA2113229C (fr) * 1994-01-11 1999-04-20 Mark Pines Compositions anti-fibreuses contenant de la quinazolinone et methodes d'utilisation correspondantes
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Also Published As

Publication number Publication date
US6028075A (en) 2000-02-22
DE69838099T2 (de) 2008-04-30
US6420371B1 (en) 2002-07-16
IL131349A0 (en) 2001-03-19
WO1998034613A1 (fr) 1998-08-13
DE69838099D1 (de) 2007-08-30
JP2001518075A (ja) 2001-10-09
USRE39574E1 (en) 2007-04-17
CA2280850A1 (fr) 1998-08-13
EP1007044A4 (fr) 2001-03-07
AU738516B2 (en) 2001-09-20
EP1007044B1 (fr) 2007-07-18
AU6004998A (en) 1998-08-26
ATE367158T1 (de) 2007-08-15
CA2280850C (fr) 2004-01-13
KR100518106B1 (ko) 2005-10-04
KR20000070996A (ko) 2000-11-25
ES2290983T3 (es) 2008-02-16
EP1007044A1 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
EP1007044B1 (fr) Compositions pharmaceutiques contenant de la quinazolinone et destinees a la prevention de la neoformation de vaisseaux sanguins et au traitement d'affections malignes
Joussen et al. Inhibition of inflammatory corneal angiogenesis by TNP-470
KR101644440B1 (ko) 개선된 혈관신생 억제용 펩티드와 이를 유효성분으로 함유하는 혈관신생과 관련된 질환의 예방 및 치료용 조성물
AU705955B2 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
JP2005537282A (ja) セファロタキシンアルカロイドによる血管新生抑制、並びにその誘導体、組成物、および使用方法
US6090814A (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6211188B1 (en) Treatment of skin disorders
KR20210020849A (ko) 크리소파놀을 포함하는 난소암 또는 유방암의 예방 또는 치료용 약학적 조성물
AU2007335963A1 (en) Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature
WO2003074074A1 (fr) Compositions comprenant la proteine nm23 a utiliser en tant qu'inhibiteur de la metalloproteinase matricielle et de l'angiogenese
KR20210062449A (ko) 프리마퀸 디포스페이트와 그 타겟으로 usp1의 혈관누수차단 효과
IL112125A (en) Quinazolinone-containing pharmaceutical compositions
US7709538B2 (en) ST104P, an anti-angiogenic agent
EP1495766A1 (fr) Polypeptides dérivés de la protéase activatrice du facteur VII (FSAP) pour traiter les troubles liés à l'angiogénèse
WO2002051423A1 (fr) Inhibiteurs d'angiogénèse
KR20020045821A (ko) 히스톤 디아세틸라제 억제 및 암 전이 억제 효과와 항염증 효과를 나타내는 아피시딘 유도체, 이를 포함하는 약학적 조성물 및 그의 용도
WO2009068906A2 (fr) Combinaisons comprenant zd4054 et un inhibiteur 172 des kinases de la famille src

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees